CPC A61K 31/573 (2013.01) [A61K 35/17 (2013.01); A61K 38/20 (2013.01); A61P 35/00 (2018.01); A61K 45/06 (2013.01)] | 12 Claims |
1. A method of treating melanoma by reducing T cell dysfunction in a subject in need thereof comprising:
administering to the subject one or more doses of metyrapone capable of reducing glucocorticoid signaling in the tumor microenvironment,
wherein a dysfunctional immune state in the subject is decreased when glucocorticoid signaling is reduced,
whereby a tumor specific immune response is enhanced.
|
5. A method of treating colon cancer by reducing T cell dysfunction in a subject in need thereof comprising:
administering to the subject one or more doses of metyrapone capable of reducing glucocorticoid signaling in the tumor microenvironment,
wherein a dysfunctional immune state in the subject is decreased when glucocorticoid signaling is reduced,
whereby a tumor specific immune response is enhanced.
|
9. A method of treating stomach cancer by reducing T cell dysfunction in a subject in need thereof comprising:
administering to the subject one or more doses of metyrapone capable of reducing glucocorticoid signaling in the tumor microenvironment,
wherein a dysfunctional immune state in the subject is decreased when glucocorticoid signaling is reduced,
whereby a tumor specific immune response is enhanced.
|